
|Articles|April 1, 2003
Imiquimod Benefits Kids Off-Label
Bal Harbour, Fla. - The use of topically applied immune response modifier imiquimod (Aldara) goes beyond its FDA-approved application for the treatment of genital and perianal warts.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















